TX-MARY-KAY
Mary Kay Inc., a global beauty company and leader in skin care innovation, continues its ongoing support of the beauty and scientific communities by participating in two major global conferences in Europe this month: the 24th World Congress of Dermatology (WCD), June 10–15 in Milan, Italy and the 5th Future of Formulations in Cosmetics Summit, June 19-20, in Dusseldorf, Germany.
Held every four years, the World Congress of Dermatology is the largest dermatology meeting in the world. The WCD’s 2019 theme, “A New Era for Global Dermatology,” was the perfect match for Mary Kay to present its applied science findings and continue the scientific conversation around pollution and skin damage. On June 12, Mary Kay will host a symposium at the event titled “Environmental Stressors and Skin: Beyond UV.”
The symposium will explore the impact of external environmental aggressors on skin health, with a focus on Europe and how antioxidants can help reduce the damaging effects of pollution. Moderated by Michelle Hines, Ph.D., Director, Global Upstream Research & Technology at Mary Kay, the symposium will feature two renowned European skin experts:
- Jean Krutmann , M.D., Professor & Director at Leibniz Research Institute for Environmental Medicine – Dusseldorf, Germany.
- Stefanie Williams, M.D., Dermatologist & Medical Director at EUDELO – London, United Kingdom.
The extent of air pollution’s impact on skin and overall health was recently revealed in a new comprehensive global review by the Forum of International Respiratory Societies’ Environmental Committee, that reported air pollution may potentially affect every organ in the human body.* The report is especially relevant to the European region, as many European cities have been found to exceed air pollution limits set by the World Health Organization (WHO) or the European Environment Agency (EEA).
In fact, more than 40 towns and cities in the UK alone exceed WHO air pollution limits** and the EEA named 15 cities that are worst affected by dust particle, nitrogen dioxide and sulfur dioxide pollution*** in Germany. Excessive levels of pollution have adverse impact on overall health and are also detrimental to skin health, texture and appearance.
A pioneer of environmental medicine, Professor Krutmann has been relentlessly working in the field of skin protection. “Since I discovered in 2010 that air pollution causes skin aging and skin pigmentation, my institute has conducted a lot of research to verify this observation and to unravel the underlying mechanisms. From these studies it is now clear that long term exposure to traffic-related particulate matter (PM) is not only dangerous for our lungs and cardiovascular system, but skin health is compromised as well,” stated Jean Krutmann, M.D.
Stefanie Williams, M.D., further explained: “We might not be able to separate the damage caused to the skin by UV exposure from those caused by air pollution clinically; however, given the major research advances made in skin and air pollution science, my expectation is that the adverse effects of pollution on skin health will continue to have a growing impact in the future in high-density cities," explained Dr. Williams.
During Mary Kay’s presentation at the 5th Future of Formulations in Cosmetics Summit, Michelle Hines, Ph. D. will reveal Mary Kay’s latest research on an antioxidant complex that helps delay the onset of premature signs of skin aging related to the damaging effects of diesel exhaust particles (DEP). The breakthrough technology, found in the Mary Kay® TimeWise® Miracle Set 3D™ skin care line, provides a powerful free-radical fighting regimen with an exclusive, patent-pending, three-dimensional approach to skin aging.
“Experts have confirmed the significant negative impact of air pollution on skin and this impact will continue to grow as environmental stressors, such as DEP, and pollution levels increase, especially in densely populated urban areas,” Dr. Hines noted. “Mary Kay has discovered targeted technologies that help delay the onset of premature skin aging from unavoidable environmental and lifestyle stressors. Simultaneously, Mary Kay has been advancing scientific discussions with renowned experts around the globe to drive awareness on the negative impact of pollution on skin.”
As one of the world’s leading cosmetics and skincare industry innovators, Mary Kay’s participation in the 24th World Congress of Dermatology and the 5th Future of Formulations in Cosmetics Summit, are the latest installments in a series of global partnerships with the scientific and academic international communities.
Further demonstrating its long-lasting commitment to funding and contributing to skin health research, Mary Kay has also presented research on the topic of skin and pollution in North America at the International Investigative Dermatology meeting in May 2018, in Orlando, Florida, and in Latin America at the Reunion Anual de Dermatologos Latinoamericanos , in May 2019, in Buenos Aires, Argentina.
Every year, Mary Kay invests millions of dollars in research and development, and conducts hundreds of thousands of scientific tests on products and ingredients to ensure the highest standards of safety, quality and performance. Mary Kay holds more than 1,500 patents for products, technologies and packaging designs in its global portfolio.
*Review by the Forum of International Respiratory Societies’
Environmental Committee, Part 1: The Damaging Effects of Air Pollution
(February 2019)
** WHO Global Ambient Air Quality Database
(update 2018)
***Report by
Bundesministerium für Umwelt, Naturschutz, Bau und Reaktorsicherheit,
Berlin, Germany. 2015 (Translation: Federal Ministry for Environment,
Nature Conservation, and Nuclear Safety).
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 55 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics and nutritional supplements. Through the Mary Kay Foundation™, the company has awarded more than $78 million to cancer research and causes to help end domestic violence. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at www.marykay.com
About the WCD Meeting
The World Congress of Dermatology (WCD) - is the largest Dermatology meeting in the world. It is held every four years on various continents. The 24th WCD was held in Milano and hosted by the Italian Society of Dermatology (SIDeMaST) from June 10-15, 2019 under the auspices of the International League of Dermatological Societies. It has been over 40 years since Milan last hosted the WCD. The Meeting focused on major breakthroughs and advances in Dermatology, ranging from clinical practice to research, technology and innovation. Learn more at www.wcd2019milan.org
About the 5th Future of Formulations in Cosmetics Summit
The 5th Future of Formulations in Cosmetics Summit brings together senior executives and experts from raw materials and active ingredients manufacturers, chemical companies, major associations, technology companies, brand owners, cosmetic companies, testing companies to discuss the latest changes, challenges and developments within the industry. The 5th Future of Formulations in Cosmetics Summit will be held in Dusseldorf in Germany on June 19-20, 2019.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190609005044/en/
Contact:
Mary Kay Inc. Corporate Communications marykay.com/newsroom 972.687.5332 or media@mkcorp.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
